Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-03-18
2008-03-18
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100
Reexamination Certificate
active
10509194
ABSTRACT:
This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.
REFERENCES:
patent: 5002874 (1991-03-01), Kaufman
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 6254862 (2001-07-01), Little et al.
patent: 2004/0132675 (2004-07-01), Kuo et al.
patent: 2006/0233753 (2006-10-01), Bonastre et al.
patent: 98/35028 (1998-08-01), None
patent: WO99/57296 (1999-11-01), None
patent: 01/35970 (2001-05-01), None
Zhao et al., “Absence of virus-associated (VA) RNA coding regions in canine adenoviral genomes,” Bingdu Xuebo 13(1):54-58, 1997, Abstract only.
Thimmappaya et al., “Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection,” Cell 31: 543-551, 1982.
Alemany et al., “Replicative adenoviruses for cancer therapy”,Nature Biotechnology18, 723-727, 2000.
Bergmann et al., “A genetically Engineered Influenza A Virus withras-Dependent Oncolytic Properties”,Cancer Research, 61: 8188-8193, 2001.
Fowlkes et al., “Transcriptional Control Regions of the Adenovirus VAI RNA Gene”Cell22, 405-413, 1980.
Fueyo et al., “A Mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo”,Oncogene19, 2-12, 2000.
Gunnery et al. “Termination Sequence Requirements Vary among Genes Transcribed by RNA polymerase III”Journal of Molecular Biology286 745-757, 1999.
Ma et al. “Sturcture, Funcsion, and Evolution of Adenovirus-Associated RNA: a Phylogenetic Approach”,Journal of Virology70(8), 5083-5099, 1996.
Mundschau et al., “OncogenicrasInduces an Inhibitor of Double-stranded RNA-dependent Eukaryotic Initiation Factor 2α-kinase Activation”,Journal of Biological Chemistry, 267(32):23092-23098, 1992.
Norman et al., “Reovirus as a novel oncolytic agent”,Journal of Clinical Investigation105: 1035-1038, 2000.
Stojdl et al., “Exploiting tumor-specific defects in the interferonpathway with a previously unknown oncolytic virus”,Nature Medicine6)7): 821-825, 2000.
Cascallo et al., “Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses,” Hum. Gene Ther. 17(9):929-40 (2006).
Furtado et al., “Functional dissection of adenovirus VAI RNA,” J. Virol. 63(8):3423-3434 (1989).
Bonastre Ramon Alemany
Piqueras Manel Maria
Fish & Richardson P.C.
Oncolytics Biotech Inc.
Priebe Scott D.
LandOfFree
Use of adenoviruses mutated in the VA genes for cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of adenoviruses mutated in the VA genes for cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of adenoviruses mutated in the VA genes for cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930701